CIK 0001232524 · Large accelerated filer
Jazz Pharmaceuticals plc
Sign in to watch- Ticker
- JAZZ
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Ireland
- Entity type
- operating
- EIN
- 981032470
- Phone
- 353-1-634-7800
- Business address
- FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, Ireland, D04 E5W7
- Former names
- JAZZ PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,420,682
- in 10 filings, $24.9M under 10b5-1 plans
Net −$41,420,682. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- COZADD BRUCE C −$20.4M Director sold 20% of stake
- Iannone Robert −$19.2M EVP, Global Head of R&D & CMO sold 54% of stake
- GALA RENEE D −$1.2M President & CEO sold 3% of stake
- Carr Patricia −$327K SVP, Chief Accounting Officer sold 18% of stake
- Patil Neena M −$289K EVP & Chief Legal Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-05 | Patil Neena M EVP & Chief Legal Officer | Shares withheld for taxes | −5,000 | $188.69 | $943K | 53,818 |
| 2026-03-05 | Iannone Robert EVP, Global Head of R&D & CMO | Shares withheld for taxes | −6,209 | $188.69 | $1.2M | 88,871 |
| 2026-03-05 | GALA RENEE D President & CEO | Shares withheld for taxes | −7,065 | $188.69 | $1.3M | 152,630 |
| 2026-03-05 | COZADD BRUCE C Director | Shares withheld for taxes | −15,114 | $188.69 | $2.9M | 390,682 |
| 2026-03-03 | COZADD BRUCE C Director | Sale 10b5-1 | −3,159 | $186.09 | $588K | 408,637 |
| 2026-03-03 | COZADD BRUCE C Director | Sale 10b5-1 | −2,608 | $186.73 | $487K | 406,029 |
| 2026-03-03 | COZADD BRUCE C Director | Sale 10b5-1 | −233 | $187.84 | $44K | 405,796 |
| 2026-02-27 | Carr Patricia SVP, Chief Accounting Officer | Sale | −1,117 | $190.91 | $213K | 9,235 |
| 2026-02-27 | RIEDEL NORBERT G Director | Option exercise | +3,415 | $138.08 | $472K | 10,439 |
| 2026-02-27 | RIEDEL NORBERT G Director | Sale | −3,415 | $192.00 | $656K | 7,024 |
| 2026-02-27 | RIEDEL NORBERT G Director | Option exercise · Non-Qualified Stock Option (right to buy) | −3,415 | 0 | ||
| 2026-02-26 | Johnson Philip L EVP & Chief Financial Officer | Grant or award | +11,857 | 62,223 | ||
| 2026-02-26 | Henderson Mary Elizabeth SVP, Technical Operations | Grant or award | +4,447 | 34,071 | ||
| 2026-02-26 | Henderson Mary Elizabeth SVP, Technical Operations | Sale | −5,343 | $194.49 | $1.0M | 28,728 |
| 2026-02-26 | Pearce Samantha EVP, Chief Commercial Officer | Grant or award | +9,782 | 52,775 | ||
| 2026-02-26 | Carr Patricia SVP, Chief Accounting Officer | Grant or award | +2,223 | 11,605 | ||
| 2026-02-26 | Carr Patricia SVP, Chief Accounting Officer | Sale | −1,253 | $194.11 | $243K | 10,352 |
| 2026-02-26 | Patil Neena M EVP & Chief Legal Officer | Option exercise | +20,125 | $113.10 | $2.3M | 73,464 |
| 2026-02-26 | Patil Neena M EVP & Chief Legal Officer | Sale | −16,602 | $192.53 | $3.2M | 56,862 |
| 2026-02-26 | Patil Neena M EVP & Chief Legal Officer | Option exercise | +875 | $113.10 | $99K | 57,737 |
Page 6 of 19 · 365 trades